Skip to main content
Livermore
Livermore
ZHEN

Great Point Partners LLC

SEC CIK
0001281446
Latest filing
Aug 14, 2026

Holdings in Q2 2022

Holdings as of Jun 30, 2022, filed Aug 15, 2022. Long positions only; changes compare share counts with Q1 2022.

Institution overview
Positions
33
+4 vs. Q1 2022
Portfolio value
$388.1M
−$25.1M (−6.1%) vs. Q1 2022
Filed
Aug 15, 2022
SEC
Holdings of Great Point Partners LLC in Q2 2022
SecurityClassSharesValue% of portfolioShare changeActionHistory
SYRESpyre Therapeutics, Inc.COM2,500,000$1.26M0.3%+2,500,000NewHistory
DNTHDianthus Therapeutics, Inc.COM1,170,000$1.40M0.4%00.0%UnchangedHistory
MLTXMoonLake ImmunotherapeuticsCLASS A ORD432,000$2.27M0.6%+432,000NewHistory
PLRXPliant Therapeutics, Inc.COM357,263$2.86M0.7%+357,263NewHistory
ETNB89bio, Inc.COM1,400,000$4.51M1.2%+1,400,000NewHistory
ALPNAlpine Immune Sciences, Inc.COM538,819$4.58M1.2%+538,819NewHistory
Pieris Pharmaceuticals Inc720795103COM2,512,500$4.70M1.2%+313,424+14.3%Added–
SLNSilence Therapeutics plcADS401,449$4.76M1.2%−42,994−9.7%ReducedHistory
VTYXVentyx Biosciences, Inc.COM389,223$4.76M1.2%+52,889+15.7%AddedHistory
KDNYChinook Therapeutics, Inc.COM336,731$5.89M1.5%−1,086,951−76.3%ReducedHistory
ABOSAcumen Pharmaceuticals, Inc.COM1,515,000$7.12M1.8%+586,718+63.2%AddedHistory
URGNUroGen Pharma Ltd.COM873,424$7.15M1.8%00.0%UnchangedHistory
Avidity Biosciences, Inc.05370A108COM500,000$7.26M1.9%00.0%Unchanged–
NBIXNeurocrine Biosciences IncStock75,000$7.31M1.9%+75,000NewHistory
ANABAnaptysbio, IncCOM453,118$9.20M2.4%−246,882−35.3%ReducedHistory
DTILPrecision Biosciences IncCOM5,755,396$9.21M2.4%+5,755,396NewHistory
ALKSAlkermes plc.SHS361,636$10.8M2.8%+361,636NewHistory
TCDATricida, Inc.COM1,164,763$11.3M2.9%−85,237−6.8%ReducedHistory
KNSAKiniksa Pharmaceuticals International, plcCOM CL A1,204,028$11.7M3.0%+85,961+7.7%AddedHistory
NKTRNektar TherapeuticsCOM3,150,000$12.0M3.1%+3,150,000NewHistory
CINCCinCor Pharma, Inc.COM669,200$12.6M3.2%+589,530+740.0%AddedHistory
RLMDRelmada Therapeutics, Inc.COM700,000$13.3M3.4%−90,000−11.4%ReducedHistory
SRPTSarepta Therapeutics, Inc.COM193,900$14.5M3.7%+193,900NewHistory
KALVKalVista Pharmaceuticals, Inc.COM1,530,000$15.1M3.9%+655,803+75.0%AddedHistory
ACRSAclaris Therapeutics, Inc.COM1,083,000$15.1M3.9%+140,555+14.9%AddedHistory
PNTPOINT Biopharma Global Inc.COM2,420,501$16.5M4.2%+360,501+17.5%AddedHistory
KRTXKaruna Therapeutics, Inc.COM149,000$18.9M4.9%+149,000NewHistory
LKFTLakefront Biotherapeutics NVSPON ADR360,000$20.1M5.2%00.0%UnchangedHistory
PCVXVaxcyte, Inc.COM985,153$21.4M5.5%+100,000+11.3%AddedHistory
TVTXTravere Therapeutics, Inc.COM971,233$23.5M6.1%−38,767−3.8%ReducedHistory
CYTKCytokinetics IncCOM NEW610,000$24.0M6.2%−40,000−6.2%ReducedHistory
JAZZJazz Pharmaceuticals plcSHS USD190,000$29.6M7.6%+35,000+22.6%AddedHistory
XENEXenon Pharmaceuticals Inc.COM1,104,334$33.6M8.7%+184,334+20.0%AddedHistory

Options (2)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Great Point Partners LLC in Q2 2022
SecurityClassPutsCalls
ALNYAlnylam Pharmaceuticals, Inc.COM$21.9M–
KRTXKaruna Therapeutics, Inc.COM$6.95M–

Sold out since Q1 2022 (7)

Positions held at the end of Q1 2022 that are gone from this filing.

Positions of Great Point Partners LLC sold out since Q1 2022
SecurityClassShares in Q1 2022Value in Q1 2022% of portfolio in Q1 2022History
EXELExelixis, Inc.COM1,300,000$29.5M7.1%History
BCYCBicycle Therapeutics PLCSPONSORED ADS550,592$24.2M5.8%History
VRTXVertex Pharmaceuticals IncStock85,000$22.2M5.4%History
RIGLRigel Pharmaceuticals IncCOM NEW4,000,000$12.0M2.9%History
ARDXArdelyx, Inc.COM4,761,905$5.09M1.2%History
PASGPassage BIO, Inc.COM113,900$353.0K0.1%History
RFLRafael Holdings, Inc.COM CL B121,000$304.0K0.1%History